Live News EQUITY L impact Jul 24, 2026, 12:08 PM UTC

ZVRA -31% premarket after EMA panel issues negative opinion on Zevra arimoclomol EU marketing application for Niemann-Pick disease type C

ZVRA -31% premarket after EMA panel issues negative opinion on Zevra arimoclomol EU marketing application for Niemann-Pick disease type C

SquawkNews Newsroom

ZVRA -31% premarket after EMA panel issues negative opinion on Zevra arimoclomol EU marketing application for Niemann-Pick disease type C